We are extremely disappointed that talks to reach a price agreement that would have made advanced breast cancer drug Enhertu available to around 1000 women in England and Wales have not been ...

The appraisal committee has prepared final draft guidance (FDG) on crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over and submitted it to NICE. The FDG has been ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

Crovalimab is recommended, within its marketing authorisation, as an option for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over who weigh 40 kg or more. It is recommended for ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

Is this treatment right for me? Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be ...

There is a commercial arrangement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] for ...

There is a simple discount patient access scheme for crovalimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Crovalimab (Piasky) is available on the NHS. It is a possible treatment for paroxysmal nocturnal haemoglobinuria in people 12 years and over who weigh 40 kg or more and: have haemolysis with clinical ...